<p>Fold of change: (+) assigns that N<sup>297</sup>glycan amounts in ALS IgG are higher relative to N<sup>297</sup>glycans from healthy control IgG and (−) assigns the contrary.</p
<p>Serum and CSF measurements of NfL correlated in the disease groups (A): Alzheimer’s disease (AD) ...
<p>Patients with a Guillain-Barré syndrome (GBS) (79.4 pg/ml) or Amyotrophic lateral sclerosis (ALS)...
© 2014 Elsevier B.V. All rights reserved.Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal ...
<p>Fold of change: (+) assigns that N-glycan amounts in ALS sera are higher relative to glycans from...
<p>ANOVA t-test analysis of glycan amounts in individual or in pooled serum samples of healthy contr...
<div><p>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by degenerat...
<p>(A) Palmitoleate to palmitate ratio (16:1/16:0) in serum and blood cells from ALS patients (ALS) ...
<p><b>Comparison of absolute concentration of IgG4 S0, S1, and S2 glycans between IgG4RD and healthy...
<p>(A) 37 glycan fractions have a significant difference in IgG and IgM binding (p<0.05). Represente...
<p>M: male; F: Female. B: bulbar onset; L: limb onset; MFO: interval from the observation of initial...
<p>Note: Measurement data are expressed as means ± standard deviations;</p><p><i>P1</i>: comparison ...
<p>FACS histograms presenting a shift in binding of serum pools of ALS patients to human neuroblasto...
Objective: Little is known whether disease clinical stage would influence the serological values in ...
<p><b>(</b>A) Acid activated protein lysates from human muscle biopsy samples were assessed for TGF-...
<p>Relative fluorescence ratios were calculated as the fluorescence intensity for each glycan analog...
<p>Serum and CSF measurements of NfL correlated in the disease groups (A): Alzheimer’s disease (AD) ...
<p>Patients with a Guillain-Barré syndrome (GBS) (79.4 pg/ml) or Amyotrophic lateral sclerosis (ALS)...
© 2014 Elsevier B.V. All rights reserved.Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal ...
<p>Fold of change: (+) assigns that N-glycan amounts in ALS sera are higher relative to glycans from...
<p>ANOVA t-test analysis of glycan amounts in individual or in pooled serum samples of healthy contr...
<div><p>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease caused by degenerat...
<p>(A) Palmitoleate to palmitate ratio (16:1/16:0) in serum and blood cells from ALS patients (ALS) ...
<p><b>Comparison of absolute concentration of IgG4 S0, S1, and S2 glycans between IgG4RD and healthy...
<p>(A) 37 glycan fractions have a significant difference in IgG and IgM binding (p<0.05). Represente...
<p>M: male; F: Female. B: bulbar onset; L: limb onset; MFO: interval from the observation of initial...
<p>Note: Measurement data are expressed as means ± standard deviations;</p><p><i>P1</i>: comparison ...
<p>FACS histograms presenting a shift in binding of serum pools of ALS patients to human neuroblasto...
Objective: Little is known whether disease clinical stage would influence the serological values in ...
<p><b>(</b>A) Acid activated protein lysates from human muscle biopsy samples were assessed for TGF-...
<p>Relative fluorescence ratios were calculated as the fluorescence intensity for each glycan analog...
<p>Serum and CSF measurements of NfL correlated in the disease groups (A): Alzheimer’s disease (AD) ...
<p>Patients with a Guillain-Barré syndrome (GBS) (79.4 pg/ml) or Amyotrophic lateral sclerosis (ALS)...
© 2014 Elsevier B.V. All rights reserved.Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal ...